Vascular Endothelial Growth Factor 165 (VEGF165) Activities Are Inhibited by Carboxymethyl Benzylamide Dextran That Competes for Heparin Binding to VEGF165 and VEGF165·KDR Complexes
Open Access
- 1 October 2001
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (43) , 39748-39754
- https://doi.org/10.1074/jbc.m101117200
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rateProceedings of the National Academy of Sciences, 1998
- Mechanisms of angiogenesisNature, 1997
- The Biology of Vascular Endothelial Growth FactorEndocrine Reviews, 1997
- Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutantNature, 1994
- Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model.Journal of Clinical Investigation, 1994
- Vascular endothelial growth factor and its receptorsProgress in Growth Factor Research, 1994
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels.The Journal of Experimental Medicine, 1991
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGFScience, 1989